Full Text View
Tabular View
No Study Results Posted
Related Studies
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
This study has been completed.
Study NCT00044759   Information provided by Wyeth
First Received: September 4, 2002   Last Updated: October 8, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hematologic Neoplasms
Additional conditions recognized in this trial
Lymphoma
Neoplasms
More general conditions related to this trial
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Interventions listed in this trial
Piperacillin/Tazobactam (Tazocin)
Additional drug interventions recognized in this trial
Penicillanic Acid
Piperacillin
Piperacillin-tazobactam combination product
Tazobactam
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Wyeth


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services